Shares of Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) have been given a consensus rating of “Buy” by the seven research firms that are presently covering the firm, MarketBeat.com reports. Three research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $5.42.
Several equities analysts recently commented on the stock. HC Wainwright upped their price target on shares of Catabasis Pharmaceuticals from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Monday, August 14th. Zacks Investment Research lowered shares of Catabasis Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 16th. Citigroup Inc. set a $3.50 price target on shares of Catabasis Pharmaceuticals and gave the stock a “hold” rating in a research report on Thursday, October 5th. Cowen and Company reaffirmed a “market perform” rating and set a $2.00 price target on shares of Catabasis Pharmaceuticals in a research report on Friday, October 6th. Finally, Oppenheimer Holdings, Inc. upped their price target on shares of Catabasis Pharmaceuticals from $4.00 to $7.00 and gave the stock an “outperform” rating in a research report on Thursday, October 5th.
Catabasis Pharmaceuticals (NASDAQ:CATB) opened at $1.82 on Friday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.73 and a current ratio of 3.73. Catabasis Pharmaceuticals has a one year low of $1.08 and a one year high of $5.51.
Catabasis Pharmaceuticals (NASDAQ:CATB) last announced its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.02. The firm had revenue of $0.25 million for the quarter. analysts expect that Catabasis Pharmaceuticals will post -1.42 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “Catabasis Pharmaceuticals, Inc. (CATB) Receives Average Recommendation of “Buy” from Brokerages” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark laws. The original version of this story can be accessed at https://www.dispatchtribunal.com/2017/11/12/catabasis-pharmaceuticals-inc-catb-receives-average-recommendation-of-buy-from-brokerages.html.
Institutional investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC acquired a new stake in shares of Catabasis Pharmaceuticals in the first quarter worth $106,000. Oppenheimer & Co. Inc. increased its position in shares of Catabasis Pharmaceuticals by 33.3% in the second quarter. Oppenheimer & Co. Inc. now owns 120,000 shares of the biotechnology company’s stock worth $169,000 after acquiring an additional 30,000 shares in the last quarter. Virtu KCG Holdings LLC acquired a new stake in shares of Catabasis Pharmaceuticals in the second quarter worth $271,000. Finally, Wedbush Securities Inc. increased its position in shares of Catabasis Pharmaceuticals by 2,368.6% in the third quarter. Wedbush Securities Inc. now owns 251,802 shares of the biotechnology company’s stock worth $534,000 after acquiring an additional 241,602 shares in the last quarter. 32.53% of the stock is owned by institutional investors.
Catabasis Pharmaceuticals Company Profile
Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.
Receive News & Ratings for Catabasis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.